person · Reporting owner
Gallagher Carol Giltner
Disclosed activity across 11 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director | February 02, 2018 | February 06, 2018 |
| Annexon, Inc.ANNX · Entity 5011 | Director | July 23, 2020 | July 23, 2020 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | June 10, 2025 | June 13, 2025 |
| Certara, Inc.CERT · Entity 787 | Director | June 15, 2021 | June 16, 2021 |
| Metacrine, Inc.MTCR · Entity 115177 | Director | September 15, 2020 | September 15, 2020 |
| PMV Pharmaceuticals, Inc.PMVP · Entity 7062 | Director | June 04, 2026 | June 05, 2026 |
| TRex Bio, Inc.TRXB · Entity 184308 | Director | October 08, 2026 | October 09, 2026 |
| Tempest Therapeutics, Inc.MLND · Entity 7734 | Director | June 22, 2020 | June 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date February 02, 2018 · Filed February 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.81 · Expires 2028-02-01 | Direct | 6,000 |
Reported balance
After 2018-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-02 · Grant · Acquired 6,000 · Balance 6,000 F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
Annexon, Inc.
Report date July 23, 2020 · Filed July 23, 2020
This filing explicitly reported no securities owned.
Atara Biotherapeutics, Inc.
Report date June 10, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,012 |
Reported balance
After 2025-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-10 · Grant · Acquired 7,828 · Balance 33,012 F1: These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. F2: This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
F2: This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024.
Certara, Inc.
Report date June 15, 2021 · Filed June 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,059 |
Reported balance
After 2021-06-15 transaction · row 1
1 source rowRow 1 · 2021-06-15 · Grant · Acquired 7,059 · Balance 7,059 F1: Represents 7,059 restricted stock units ("RSU") granted under the Certara Inc. 2020 Incentive Plan that will entitle the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Company's next annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 7,059 restricted stock units ("RSU") granted under the Certara Inc. 2020 Incentive Plan that will entitle the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Company's next annual stockholder meeting.
Metacrine, Inc.
Report date September 15, 2020 · Filed September 15, 2020
This filing explicitly reported no securities owned.
PMV Pharmaceuticals, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2036-06-04 | Direct | 42,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 42,000 · Balance 42,000 F1: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2036-06-04 | Direct | 0 |
Reported balance
After 2026-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-04 · Gift · Disposed 42,000 · Balance 0 F1: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2036-06-04 | IndirectSee footnote | 42,000 |
Reported balance
After 2026-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-04 · Gift · Acquired 42,000 · Balance 42,000 F1: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. F2: The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.
F2: The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee.
TRex Bio, Inc.
Report date October 08, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2036-10-08 | Direct | 17,500 |
Reported balance
After 2026-10-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-08 · Grant · Acquired 17,500 · Balance 17,500 F1: The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date.
Tempest Therapeutics, Inc.
Report date June 22, 2020 · Filed June 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2030-06-21 | Direct | 12,000 |
Reported balance
After 2020-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-22 · Grant · Acquired 12,000 · Balance 12,000 F1: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Frazier Lifesciences Acquisition Corp
Report date November 22, 2022 · Filed November 23, 2022
Section 16 reporting ended · disclosed 2022-11-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-11-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-22 · Exercise / conversion · Disposed 30,000 · Balance 0 F1: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022.
Mirati Therapeutics, Inc.
Report date January 23, 2024 · Filed January 24, 2024
Section 16 reporting ended · disclosed 2024-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,808 |
Reported balance
After 2024-01-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-01-23 · Disposition to issuer · Disposed 7,555 · Balance 6,808 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-01-23 · Disposition to issuer · Disposed 6,808 · Balance 0 F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $38.02 · Expires 2033-06-21 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-23 · Disposition to issuer · Disposed 12,784 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS.
F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.
F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.
F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Turning Point Therapeutics, Inc.
Report date August 17, 2022 · Filed August 17, 2022
Section 16 reporting ended · disclosed 2022-08-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.39 · Expires 2030-06-14 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-17 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.64 · Expires 2031-06-01 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-17 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.99 · Expires 2029-07-23 | IndirectBy the Gallagher Revocable Trust dated May 10, 2011 | 0 |
Reported balance
After 2022-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-17 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").
F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2018 Filed Dec 12, 2018 00:38 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantCommon Stock | 8,249 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-062111 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,249 F1 · price: Received in exchange for 110,887 shares of Millendo Therapeutics, Inc. common stock in connection with merger of Millendo Therapeutics, Inc. into the Issuer. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 00:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 21,374 | $36.38 | $777,586.12 |
DisclosureSEC source: 0001209191-18-057696 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,818 F1 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.87 to $36.84. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 20:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 400 | $45.29 | $18,116.00 |
DisclosureSEC source: 0001209191-18-038568 · doc4.xml · nonDerivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,192 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.25 to $45.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 20:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,100 | $44.68 | $93,828.00 |
DisclosureSEC source: 0001209191-18-038568 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,592 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $44.10 to $45.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-18-038309 · doc4.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-06-13 F2 · derivative.exercise_date: The option shall vest on June 14, 2019, subject to the Reporting Person's continuous service. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038309 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,692 F1 · shares: These restricted stock units shall vest on June 14, 2019, subject to the Reporting Person's continuous service. Read SEC document |
| May 16, 2018 Filed May 17, 2018 00:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 273 | $46.06 | $12,574.38 |
DisclosureSEC source: 0001209191-18-030723 · doc4.xml · nonDerivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,192 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030723 · doc4.xml · derivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F4 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from March 25, 2014, subject to the holder's continuous service through each such date. F5 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recipient's termination date. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030723 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 01:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,183 | $46.50 | $55,009.50 |
DisclosureSEC source: 0001209191-18-011674 · doc4.xml · nonDerivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,920 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016. Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 01:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 817 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011674 · doc4.xml · derivative · entry 5 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545 Underlying: Common Stock · 817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from March 25, 2014, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recipient's termination date. Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 01:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 1,548 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011674 · doc4.xml · derivative · entry 4 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,548 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F4 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from January 30, 2014, subject to the holder's continuous service through each such date. F5 · derivative.expiration_date: The earlier of (i) January 30, 2021 or (ii) the second anniversary of termination date. Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 01:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 817 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011674 · doc4.xml · nonDerivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 01:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,548 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011674 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| February 02, 2018 Filed Feb 6, 2018 21:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $104.81 | $0.00 |
DisclosureSEC source: 0001209191-18-007828 · doc4.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-02-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 23:24 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,184 | $14.20 | $16,812.80 |
DisclosureSEC source: 0001209191-17-061600 · doc4.xml · nonDerivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,738 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:24 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 817 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061600 · doc4.xml · derivative · entry 5 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,362 Underlying: Common Stock · 817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from March 25, 2014, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recipient's termination date. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:24 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 1,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061600 · doc4.xml · derivative · entry 4 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,548 Underlying: Common Stock · 1,549 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F4 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from January 30, 2014, subject to the holder's continuous service through each such date. F5 · derivative.expiration_date: The earlier of (i) January 30, 2021 or (ii) the second anniversary of termination date. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:24 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 817 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061600 · doc4.xml · nonDerivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:24 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061600 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 21:38 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,184 | $14.30 | $16,931.20 |
DisclosureSEC source: 0001209191-17-049452 · doc4.xml · nonDerivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,556 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 21:38 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 818 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049452 · doc4.xml · derivative · entry 5 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,179 Underlying: Common Stock · 818 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from March 25, 2014, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recipient's termination date. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 21:38 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 1,548 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049452 · doc4.xml · derivative · entry 4 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,097 Underlying: Common Stock · 1,548 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F4 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from January 30, 2014, subject to the holder's continuous service through each such date. F5 · derivative.expiration_date: The earlier of (i) January 30, 2021 or (ii) the second anniversary of termination date. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 21:38 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 818 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049452 · doc4.xml · nonDerivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 21:38 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,548 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049452 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 21:29 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,000 | $13.15 | $13,150.00 |
DisclosureSEC source: 0001209191-17-039239 · doc4.xml · nonDerivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,374 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:29 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001209191-17-039239 · doc4.xml · derivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2027-06-08 F3 · derivative.exercise_date: The option shall vest on June 8, 2018, subject to the Reporting Person's continuous service. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:29 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039239 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,374 F1 · shares: These restricted stock units shall vest on June 8, 2018, subject to the Reporting Person's continuous service. Read SEC document |
| May 16, 2017 Filed May 17, 2017 21:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,184 | $15.25 | $18,056.00 |
DisclosureSEC source: 0001209191-17-033206 · doc4.xml · nonDerivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,374 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 817 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033206 · doc4.xml · derivative · entry 5 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,997 Underlying: Common Stock · 817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from March 25, 2014, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recipient's termination date. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 1,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033206 · doc4.xml · derivative · entry 4 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,645 Underlying: Common Stock · 1,549 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F4 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from January 30, 2014, subject to the holder's continuous service through each such date. F5 · derivative.expiration_date: The earlier of (i) January 30, 2021 or (ii) the second anniversary of termination date. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 817 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033206 · doc4.xml · nonDerivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033206 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:53 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $24.60 | $0.00 |
DisclosureSEC source: 0001209191-17-015458 · doc4.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-02-23 F1 · derivative.exercise_date: The stock option vests and becomes fully exercisable on February 24, 2018. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 01:12 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,183 | $16.10 | $19,046.30 |
DisclosureSEC source: 0001209191-17-011769 · doc4.xml · nonDerivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,192 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 01:12 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 817 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011769 · doc4.xml · derivative · entry 5 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,814 Underlying: Common Stock · 817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from March 25, 2014, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recipient's termination date. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 01:12 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 1,548 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011769 · doc4.xml · derivative · entry 4 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,194 Underlying: Common Stock · 1,548 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F4 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from January 30, 2014, subject to the holder's continuous service through each such date. F5 · derivative.expiration_date: The earlier of (i) January 30, 2021 or (ii) the second anniversary of termination date. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 01:12 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 817 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011769 · doc4.xml · nonDerivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 01:12 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,548 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011769 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 21:50 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionSeries D Preferred Stock · Derivative | 21,439 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006405 · doc4.xml · derivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,439 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 21:50 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionSeries C Preferred Stock · Derivative | 42,857 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006405 · doc4.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,857 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 21:50 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionCommon Stock | 64,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006405 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:20 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 5,500 | $0.00 Strike: $15.08 | $0.00 |
DisclosureSEC source: 0001209191-17-002058 · doc4.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2024-01-03 F2 · derivative.exercise_date: The option shall vest on June 8, 2017, the date of the Company's annual stockholder meeting, subject to the Reporting Person's continuous service. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:20 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002058 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,010 F1 · shares: These restricted stock units shall vest on June 8, 2017, the date of the Company's annual stockholder meeting, subject to the Reporting Person's continuous service. Read SEC document |
| November 16, 2016 Filed Nov 17, 2016 21:51 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,184 | $19.35 | $22,910.40 |
DisclosureSEC source: 0001209191-16-150910 · doc4.xml · nonDerivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,010 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:51 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 817 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150910 · doc4.xml · derivative · entry 5 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,631 Underlying: Common Stock · 817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from March 25, 2014, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recipient's termination date. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:51 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 1,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150910 · doc4.xml · derivative · entry 4 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,742 Underlying: Common Stock · 1,549 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F4 · derivative.exercise_date: The restricted stock units ("RSUs") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from January 30, 2014, subject to the holder's continuous service through each such date. F5 · derivative.expiration_date: The earlier of (i) January 30, 2021 or (ii) the second anniversary of termination date. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:51 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 817 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150910 · doc4.xml · nonDerivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:51 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 1,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150910 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.